Disruptions in Liver Function among Cancer Patients and Patients Treated with Tyrosine Kinase Inhibiting Drugs: Comparisons of Two Population-Based Databases
Table 3
Incidence of first occurrence of each degree of elevation for multiple liver function tests, cancer cohorts.
Liver function test
EMR database
Insurance claims database
Patients with elevation
Incidence rate per
Patients with elevation
Patients evaluated*
%
PY
100 PY (95% CI)
Patients evaluated*
%
PY
Incidence rate per 100 PY (95% CI)
ALT or SGPT (U/L)
>3× ULN
11419
688
6.0
17987
3.8 (1.0–10.0)
5771
36
0.6
8190
0.4 (0.3–0.6)
>5× ULN
278
2.4
18357
1.5 (0.1–6.4)
8
0.1
8216
0.1 (0–0.2)
>10× ULN
95
0.8
18532
0.5 (0–4.7)
3
0.1
8220
0.04 (0–0.1)
>20× ULN
30
0.3
18599
0.2 (0–4.0)
0
0
8220
—
AST or SGOT (U/L)
>3× ULN
11425
557
4.9
18212
3.1 (0.6–8.9)
5876
27
0.5
8377
0.3 (0.2–0.4)
>5× ULN
254
2.2
18450
1.4 (0.1–6.2)
12
0.2
8383
0.1 (0.1–0.2)
>10× ULN
99
0.9
18561
0.5 (0–4.7)
4
0.1
8390
0.05 (0–0.1)
>20× ULN
47
0.4
18597
0.3 (0–4.2)
1
0.02
8394
0.01 (0–0.1)
ALP (U/L)
>2× ULN
11384
583
5.1
18354
3.2 (0.7–9.0)
5922
32
0.5
8403
0.4 (0.2–0.5)
>3× ULN
301
2.6
18515
1.6 (0.1–6.6)
14
0.2
8417
0.2 (0.1–0.3)
>5× ULN
124
1.1
18584
0.7 (0–5.0)
4
0.1
8421
0.05 (0–0.1)
Serum bilirubin, total (mg/dL)
>1.5× ULN
11439
548
4.8
18222
3.0 (0.6–8.8)
5953
33
0.6
8471
0.4 (0.3–0.5)
>2× ULN
309
2.7
18444
1.7 (0.2–6.7)
14
0.2
8483
0.2 (0.1–0.3)
>5× ULN
98
0.9
18597
0.5 (0–4.7)
4
0.1
8489
0.05 (0–0.1)
>10× ULN
47
0.4
18614
0.3 (0–4.2)
1
0.02
8491
0.01 (0–0.1)
LFT combinations of Hy's Law
11372
52
0.5
18559
0.3 (0–4.3)
5526
2
0.04
7905
0.03 (0–0.1)
evaluated: number of eligible patients with at least one follow-up measure of the corresponding LFT. Hy’s Law = ALT or AST > 3× ULN, ALP < 2× ULN, and Bilirubin > 2× ULN. ULN: upper limit of normal; ALP: alkaline phosphatase; ALT: alanine aminotransferase; PY: person-years; SGPT: serum glutamic pyruvic transaminase; SGOT: serum glutamate-oxaloacetate transaminase.
